Ron Epelbaum
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 49
- Molecular Medicine top 1%
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research 17
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 10
- Reproductive Medicine top 2%
-
- Medical Imaging Techniques and Applications 24
- Radiopharmaceutical Chemistry and Applications 10
-
- Lung Cancer Treatments and Mutations 15
- Medical Imaging and Pathology Studies 15
-
- CNS Lymphoma Diagnosis and Treatment 11
- Co-authors
- Nissim HaimGil Bar‐SelaMoshe SchafferOra IsraelEldad J. DannMenachem Ben-ShaharRachel Bar‐ShalomZeev Blumenfeld
- Partner nations
- IsraelUnited StatesSwitzerland
In The Last Decade
Ron Epelbaum
113 papers receiving 4.6k citations
Peers
Comparison fields: 5 of 134
- Pathology and Forensic Medicine 1.6k
- Molecular Medicine 382
- Oncology 1.9k
- Cancer Research 821
- Reproductive Medicine 427
Countries citing papers authored by Ron Epelbaum
This map shows the geographic impact of Ron Epelbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Epelbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Epelbaum more than expected).
Fields of papers citing papers by Ron Epelbaum
This network shows the impact of papers produced by Ron Epelbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Epelbaum. The network helps show where Ron Epelbaum may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ron Epelbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2018 | 137 | |
| 3 | 2016 | 12 | |
| 4 | Predictors of Early Recurrence of Adenocarcinoma of the Head of the Pancreas after Curative Resection | 2015 | 2 |
| 5 | 2014 | 311 | |
| 6 | 2011 | 25 | |
| 7 | 2010 | 20 | |
| 8 | 2010 | 214 | |
| 9 | 2007 | 140 | |
| 10 | 2002 | 5 | |
| 11 | 2002 | 94 | |
| 12 | AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282) | 2000 | 13 |
| 13 | 1997 | 17 | |
| 14 | 1997 | 5 | |
| 15 | 1996 | 207 | |
| 16 | 1995 | 41 | |
| 17 | 1992 | 67 | |
| 18 | Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. | 1991 | 35 |
| 19 | 1990 | 102 | |
| 20 | 1988 | 30 |
About Ron Epelbaum
Ron Epelbaum is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine, having authored 114 papers that have together received 4.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (49 papers), Medical Imaging Techniques and Applications (24 papers), Pancreatic and Hepatic Oncology Research (17 papers), Lung Cancer Treatments and Mutations (15 papers), Medical Imaging and Pathology Studies (15 papers), CNS Lymphoma Diagnosis and Treatment (11 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.6k citations), Molecular Medicine (382 citations) and Oncology (1.9k citations). Ron Epelbaum has collaborated with scholars based in Israel, United States and Switzerland. Frequent co-authors include Nissim Haim, Gil Bar‐Sela, Moshe Schaffer, Ora Israel, Eldad J. Dann, Menachem Ben-Shahar, Rachel Bar‐Shalom, Zeev Blumenfeld, Irit Avivi and Jacob M. Rowe. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Radiology, International Journal of Radiation Oncology*Biology*Physics and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.